Tags

Type your tag names separated by a space and hit enter

Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment.
Eur Neurol. 2005; 53(4):197-202.EN

Abstract

The aim of this study was to evaluate the efficacy of the new optimised levodopa, Stalevo (levodopa, carbidopa and entacapone) in patients with Parkinson's disease experiencing end-of-dose wearing-off. Treatment with Stalevo was compared to treatment with traditional immediate-release levodopa and dopa-decarboxylase inhibitor (DDCI) formulations along with adjunct entacapone (Comtess/Comtan). A European, open, parallel-group, active treatment-controlled phase IIIb study evaluating 176 patients randomised to switch from their current regimen of levodopa/DDCI to either an equivalent dose of Stalevo or levodopa/DDCI plus entacapone. After 6 weeks, treatments were assessed using the Clinical Global Impression of Change, the Unified Parkinson's Disease Rating Scale and a Motor Fluctuations Questionnaire. Over 70% of patients in both the Stalevo and adjunct entacapone arms felt that they were clinically improved and over 80% experienced a reduction in fluctuations. Although there was no significant difference between Stalevo and levodopa/DDCI plus entacapone with regard to motor improvement and side effects, 81% of patients stated that they preferred treatment with Stalevo compared with taking two separate tablets (i.e. levodopa/DDCI and entacapone). Stalevo was well tolerated and safe when substituted for levodopa DDCI preparations.

Authors+Show Affiliations

MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK. david.brooks@csc.mrc.ac.ukNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15970632

Citation

Brooks, D J., et al. "Treatment of End-of-dose Wearing-off in Parkinson's Disease: Stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI Given in Combination With Comtess/Comtan (entacapone) Provide Equivalent Improvements in Symptom Control Superior to That of Traditional levodopa/DDCI Treatment." European Neurology, vol. 53, no. 4, 2005, pp. 197-202.
Brooks DJ, Agid Y, Eggert K, et al. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. Eur Neurol. 2005;53(4):197-202.
Brooks, D. J., Agid, Y., Eggert, K., Widner, H., Ostergaard, K., & Holopainen, A. (2005). Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. European Neurology, 53(4), 197-202.
Brooks DJ, et al. Treatment of End-of-dose Wearing-off in Parkinson's Disease: Stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI Given in Combination With Comtess/Comtan (entacapone) Provide Equivalent Improvements in Symptom Control Superior to That of Traditional levodopa/DDCI Treatment. Eur Neurol. 2005;53(4):197-202. PubMed PMID: 15970632.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. AU - Brooks,D J, AU - Agid,Y, AU - Eggert,K, AU - Widner,H, AU - Ostergaard,K, AU - Holopainen,A, AU - ,, Y1 - 2005/06/20/ PY - 2005/02/09/received PY - 2005/04/13/accepted PY - 2005/6/23/pubmed PY - 2005/9/24/medline PY - 2005/6/23/entrez SP - 197 EP - 202 JF - European neurology JO - Eur Neurol VL - 53 IS - 4 N2 - The aim of this study was to evaluate the efficacy of the new optimised levodopa, Stalevo (levodopa, carbidopa and entacapone) in patients with Parkinson's disease experiencing end-of-dose wearing-off. Treatment with Stalevo was compared to treatment with traditional immediate-release levodopa and dopa-decarboxylase inhibitor (DDCI) formulations along with adjunct entacapone (Comtess/Comtan). A European, open, parallel-group, active treatment-controlled phase IIIb study evaluating 176 patients randomised to switch from their current regimen of levodopa/DDCI to either an equivalent dose of Stalevo or levodopa/DDCI plus entacapone. After 6 weeks, treatments were assessed using the Clinical Global Impression of Change, the Unified Parkinson's Disease Rating Scale and a Motor Fluctuations Questionnaire. Over 70% of patients in both the Stalevo and adjunct entacapone arms felt that they were clinically improved and over 80% experienced a reduction in fluctuations. Although there was no significant difference between Stalevo and levodopa/DDCI plus entacapone with regard to motor improvement and side effects, 81% of patients stated that they preferred treatment with Stalevo compared with taking two separate tablets (i.e. levodopa/DDCI and entacapone). Stalevo was well tolerated and safe when substituted for levodopa DDCI preparations. SN - 0014-3022 UR - https://www.unboundmedicine.com/medline/citation/15970632/Treatment_of_end_of_dose_wearing_off_in_parkinson's_disease:_stalevo__levodopa/carbidopa/entacapone__and_levodopa/DDCI_given_in_combination_with_Comtess/Comtan__entacapone__provide_equivalent_improvements_in_symptom_control_superior_to_that_of_traditional_levodopa/DDCI_treatment_ L2 - https://www.karger.com?DOI=10.1159/000086479 DB - PRIME DP - Unbound Medicine ER -